LABORATORIO FARMAC.ERFO (RK7) — Cash Flow-to-Debt Ratio

Latest as of December 2023: 0.57x

LABORATORIO FARMAC.ERFO (RK7) has a Cash Flow-to-Debt Ratio of 0.57x as of December 2023, meaning its operating cash flow of €1.30 Million could theoretically repay 1% of its total liabilities (€2.26 Million) in one year. See LABORATORIO FARMAC.ERFO (RK7) financial flexibility to measure the company's free cash flow as a share of total liabilities.

CF-to-Debt Ratio

0.57x
Operating CF / Total Liabilities

Operating Cash Flow

€1.30 Million
EUR

Total Liabilities

€2.26 Million
EUR

Data as of

Dec 2023
Most recent filing

LABORATORIO FARMAC.ERFO Cash Flow-to-Debt Ratio (2021–2023)

Historical debt coverage capacity for LABORATORIO FARMAC.ERFO across 3 annual periods. For the full cash flow conversion analysis, see LABORATORIO FARMAC.ERFO (RK7) cash conversion ratio.

Annual Cash Flow-to-Debt Ratio for LABORATORIO FARMAC.ERFO (2021–2023)

Year-by-year debt coverage analysis for LABORATORIO FARMAC.ERFO. Check RK7 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.

Year CF-to-Debt Ratio Operating CF (EUR) Total Liabilities YoY Change
2023 0.57x €1.30 Million €2.26 Million ▲ +691.9%
2022 0.07x €761.80K €10.53 Million ▼ -93.0%
2021 1.03x €2.27 Million €2.21 Million
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.